REFERENCES
- Henderson IC, Garber JE, Bretmeyer JD, et al. Comprehensive management of disseminated breast cancer. Cancer 1990; 66: 1439–1448.
- Hudis CA, Norton L. Adjuvant drug therapy for opera-ble breast cancer. Sem Oncol 1996; 23: 475–493.
- Hoogenstraten AB, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981; 47: 207–214.
- Bonadonna G, Gianni L, Santoro A, et al. Drugs ten years later: epirubicin (review). Ann Oncol 1993; 4: 359–369.
- Johnson SA, Harper P, Hortobagyi GN, Pouillart P. Vinorelbine: an overview. Cancer Treat Rev 1996; 22: 127–142.
- Fumoleau P, Deloziers T, Extra JM, et al. Vinorelbine in the treatment of breast cancer: the european experience. Semin Oncol 1995; 22 (2): 22–29.
- Canobbio L, Boccardo F Pastorino G, et al. Phase II study of Navelbine in advanced breast cancer. Semin Oncol 1989; 16 (suppl 2): 33-36.
- Gasparini G, Caffo O, Barni S, et al. Vinorelbine is an active antiproliferative agent in pretreated advanced breast cancer patients: a phase II study. J Clin Oncol 1994; 12: 2094–2101.
- Weber BL, Vogel C, Jones S, et al. Intravenous vinorel-bine as first line and second line therapy in advanced breast cancer. J Clin Oncol 1995; 13: 2722–2730.
- Spielmann M, Dorval T, Turpin F, et al. Phase II trial of Vinorelbine/Doxorubicin as first line therapy of advanced breast cancer. J Clin Oncol 1994; 12: 1764–1770.
- Pronzato P, Queirolo P, Landucci M, et al. Phase II study of vinorelbine and Ifosfamide in anthracycline resistent metastatic breast cancer. Breast Cancer Res Treat 1997; 42: 183–186.
- Brufman G, Colajori E, Ghilezan N, et al. Doubling epirubicin dose intensity (100 mg/m2 versus 50 mg/m2) in the FEC regimen significantly increases response rates. An inter-national randomized phase III study in metastatic breast can-cer. Ann Oncol 1997; 8: 155–162.
- Pronzato P, Bertelli G, Vigani A, Vaira F. A feasibility study of accelerated polychemotherapy with cisplatin, epidox-orubicin and cyclophosphamide (PEC) in advanced ovarian cancer. Br J Cancer 1996; 73: 1425–1427.
- Ardizzoni A, Venturini M, Crind L, et al. High dose intensity chemotherapy, with accelerated cyclophosphamide, doxorubicin, etoposide and granulocyte-macrophage colony stimulating factor, in the treatment of small cell lung cancer. Eur J Cancer 1993; 29A: 687–692.
- Pronzato P, Bertelli G, Bruna F, et al. Intensified M-VEC chemotherapy with G-CSF support as outpatient treat-ment for advanced bladder cancer. Anticancer Res 1997; 17: 2325–2328.
- Ardizzoni A, Venturini M, Sertoli MR, et al. Granulocyte-macrophage colony stimulating factor allows acceleration and dose intensity increase of CEF chemothera-py: a randomized study in patients with advanced breast can-cer. Br J Cancer 1994; 69: 385–391.